ASELAGE STEVE
ASELAGE STEVE's purchase track record
ASELAGE STEVE has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/24/2024 | BCRX | $16K | +32.1% | +24.0% | +12.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Transaction History
| BCRX | ▲ Buy | Grant | 6,820 | $0 | 6/12/2024 | View on chart |
| BCRX | ▲ Buy | Open Market | 2,500 | $16K | 5/24/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 16,745 | $0 | 6/13/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 12,866 | $0 | 6/7/2022 | View on chart |
| BCRX | ▲ Buy | Grant | 569 | $5K | 5/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,575 | $56K | 5/11/2022 | View on chart |
| BCRX | ▲ Buy | Grant | 301 | $5K | 2/28/2022 | View on chart |
| BCRX | ▲ Buy | Grant | 414 | $5K | 11/30/2021 | View on chart |
| TVTX | ▼ Sell | Open Market | 31,800 | $935K | 11/16/2021 | View on chart |
| TVTX | ▼ Sell | Open Market | 10,000 | $262K | 11/5/2021 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $162K | 11/5/2021 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,500 | $105K | 11/2/2021 | View on chart |
| TVTX | ▼ Sell | Open Market | 5,000 | $147K | 11/1/2021 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 60,000 | $974K | 10/7/2021 | View on chart |
| TVTX | ▼ Sell | Open Market | 28,000 | $734K | 10/7/2021 | View on chart |
| TVTX | ▼ Sell | Open Market | 32,000 | $840K | 10/7/2021 | View on chart |
| TVTX | ▼ Sell | Gift | 3,000 | $0 | 7/16/2021 | View on chart |
| TVTX | ▼ Sell | Gift | 3,000 | $0 | 7/16/2021 | View on chart |
| TVTX | ▼ Sell | Gift | 25,000 | $0 | 2/4/2021 | View on chart |
| TVTX | ▼ Sell | Gift | 25,000 | $0 | 2/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target
BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target. BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.